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Abstract
To date, genome-wide association studies have focused almost exclusively on populations of European ancestry. These
studies continue with the advent of next-generation sequencing, designed to systematically catalog and test low-frequency
variation for a role in disease. A complementary approach would be to focus further efforts on cohorts of multiple
ethnicities. This leverages the idea that population genetic drift may have elevated some variants to higher allele frequency
in different populations, boosting statistical power to detect an association. Based on empirical allele frequency
distributions from eleven populations represented in HapMap Phase 3 and the 1000 Genomes Project, we simulate a range
of genetic models to quantify the power of association studies in multiple ethnicities relative to studies that exclusively
focus on samples of European ancestry. In each of these simulations, a first phase of GWAS in exclusively European samples
is followed by a second GWAS phase in any of the other populations (including a multiethnic design). We find that nontrivial
power gains can be achieved by conducting future whole-genome studies in worldwide populations, where, in particular,
African populations contribute the largest relative power gains for low-frequency alleles (,5%) of moderate effect that
suffer from low power in samples of European descent. Our results emphasize the importance of broadening genetic
studies to worldwide populations to ensure efficient discovery of genetic loci contributing to phenotypic trait variability,
especially for those traits for which large numbers of samples of European ancestry have already been collected and tested.
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Introduction
Over the past four years, genome-wide association studies
(GWAS) have started to reveal the genetic underpinnings of
complex traits and common diseases, yet only a modest fraction of
the heritability can be attributed to the collection of associated
variants discovered to date [1]. Even though impressive sample
sizes have been assembled through collaborative efforts, the
statistical power to discover susceptibility loci is limited by a
number of factors [2].
One limitation of the first wave of GWAS is the almost exclusive
interrogation of common variation with limited coverage of alleles
in the lower end of the frequency spectrum. Many low-frequency
alleles have not been ascertained, and even for those that were
catalogued in the dbSNP database, SNPs on the genome-wide
microarrays tag low-frequency variants only poorly through
pairwise linkage disequilibrium [3]. The second limitation is that
most GWAS to date have primarily studied samples of European
descent [4], with low power to detect association for alleles of low
frequency compared to more common alleles.
A compelling illustration of this second limitation was provided
by the recent discovery of the association at the KCNQ1 locus with
type 2 diabetes risk (with an estimated odds ratio =1.2) in two
contemporary GWAS in East-Asian population samples [5,6]. The
associated SNP (rs2283228) has a minor allele frequency of ,40%
in East-Asian samples but a minor allele frequency of ,5% in
European samples [7]. At this allele frequency, the association had
little power to be discovered (at p,5610
28) in the series of GWAS
in European-derived samples performed ahead of the two East-
Asian studies [8,9,10,11,12], even though the SNP was well tagged
in European samples. After its initial discovery in the East-Asian
samples, the association was successfully replicated as a pre-
specified hypothesis at a more liberal significance threshold. This
finding raises the question to what extent power is affected by the
focus on samples of European ancestry, and how power to detect
association of genetic variation segregating at low frequency in
European populations could be heightened by broadening GWAS
efforts to a more diverse set of populations.
To this end, we evaluate here the relative benefit of performing
future genome studies in worldwide populations (‘‘second phase’’),
preceded by an initial GWAS in a European population (‘‘first
phase’’). Using the empirically observed allele frequencies in
population samples represented by HapMap Phase 3 and the 1000
Genomes Project, we quantify the impact of frequency differences
between populations on the power to find novel association of
modest effect (GRR #1.5), assuming that genome-wide associa-
tion results are combined in the two GWAS phases. We also
address the implications of such allele frequency differences for
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12600replicating bona fide associations (most discovered in European
samples) in different populations.
Overall, we show that there are substantial power gains to be
had by focusing on large multiethnic studies. Additionally, allele
frequency fluctuations between global populations and their
impact on power must be considered in replication studies.
Methods
We computed power to detect an association at genome-wide
significance (p,5610
28) using a theoretical model of log-additive
(multiplicative) effects, allowing us to perform all calculations
efficiently. For each SNP, we separately computed the non-
centrality x
2 parameter (NCP) in the first and second phase as a
function of risk allele frequency, case-control sample size, and
assumed effect size (genotype relative risk, GRR) (Text S1). In
phase 1, we used the empirically observed allele frequencies in
CEU (Utah residents with Northern and Western European
ancestry collected by the Centre d’Etude du Polymorphisme
Humain) to mimic the fact that most GWAS to date have tested
European samples. In phase 2, we used the allele frequencies in
any of the population panels represented in HapMap 3 or 1000
Genomes (see below). For multiethnic scenarios in phase 2, we
computed the NCPs per population. By summing the NCPs in all
populations in phases 1 and 2, we derived the asymptotic power
for a given SNP to reach a p-value of 5610
28 (Text S1). For each
SNP, we averaged the power for both alleles simulated as the risk-
increasing allele (GRR .1). We repeated this procedure across all
1,440,616 SNPs present in HapMap 3 or 3,327,757 SNPs present
in 1000 Genomes, and report the average genome-wide power
across all SNPs, and the average power for SNP subsets stratified
by the minor allele frequency in CEU (where we refer to 1–5% as
low-frequency alleles). We varied the total sample size of each
scenario between 10,000, 20,000 and 80,000 samples (Table 1).
We varied the GRR between 1.1 and 1.5, following a
multiplicative risk model and assumed a fixed effect between
different populations in phases 1 and 2.
We note that our approach is not to be confused with a two-
stage replication design (as described, for example, in [13]) where
only a limited set of SNPs are taken from the phase 1 (based on
some p-value threshold) for additional testing in phase 2. Instead,
we leverage the idea that genome-wide association data sets are
combined in collaborative spirit, as is now routinely done for locus
discovery.
We obtain empirical allele frequencies for SNPs from two
sources: HapMap 3 and the 1000 Genomes Project. The HapMap
3 resource comprises genome-wide SNP data from 11 population
samples [14]: CEU (Utah residents with Northern and Western
European ancestry collected by the Centre d’Etude du Poly-
morphisme Humain), TSI (Toscans in Italy), CHB (Han Chinese
in Beijing, China), JPT (Japanese from Tokyo, Japan), CHD
(Chinese in Metropolitan Denver, Colorado), YRI (Yoruba in
Ibidan, Nigeria), MKK (Massai in Kinyawa, Kenya), LWK
(Luhya in Webuye, Kenya), ASW (African ancestry in southwest
USA), GIH (Gujarati Indians in Houston, Texas), and MXL
(Mexican ancestry in Los Angeles, California). In total, 1184
samples have been genotyped on the Illumina Human-1M and
Affymetrix 6.0 arrays, and SNP genotypes merged and processed
for quality control. Our analysis is restricted to the allele
frequencies of 1,440,616 SNPs that are QC-passing and
polymorphic in at least one of the eleven populations (referred
to as the consensus data). To remove bias due to different sample
sizes of these populations, we randomly selected 50 unrelated
founders (100 unique chromosomes, dictated by MXL, the
smallest sample) from each population in the consensus genotype
data to compute unbiased allele frequencies.
We also used frequency estimates from low-coverage sequenc-
ing data in four population panels (CEU, CHB, JPT, and YRI)
generated in Pilot 1 of the 1000 Genomes Project [15]. The data
we use here was generated in 60 founder individuals of CEU, 30 of
CHB, 30 of JPT, and 59 of YRI, resulting in three analysis panels
of similar sample size (CEU, CHB+JPT and YRI).
As a complementary analysis, we performed a power analysis
for a specific set of 182 unique SNPs (189 reported associations; 7
SNPs reported for multiple diseases) that have recently been
described as significantly associated to 26 complex diseases (taken
from http://www.genome.gov/GWAStudies/, accessed on 28
September 2009). For most of these associations, the effect sizes
range from 1.1 to 1.3. Based on the observed allele frequencies in
each of the HapMap 3 populations, we computed the sample size
required to replicate the association at 80% power (at a nominal
p,0.05) for the reported risk allele, taking the reported odds ratio
as the GRR in a multiplicative model. This analysis reflects the
testing of a specific hypothesis (instead of discovery across the
whole genome) based on bona fide associations reported by GWAS
performed to date.
Results
We compared three main scenarios where the key difference
was the total sample size (Table 1). First we explored the simple
scenario where phases 1 and 2 are performed in 5,000 samples
from the CEU population panel (Table S1). Power was, as
expected, consistently lower across the entire range of effect sizes
and allele frequencies compared to a sample size of 20,000 (Table
S2) and 80,000 (Table S3).
At a sample size of 20,000, the aggregate power across all 1.4
million SNPs considered was 82% at an effect size (GRR) of 1.5,
but fell to 8% at a GRR of 1.1 (Table S2). Across the different
effect sizes, power was largely driven by the power contribution of
common alleles (MAF .10%). At a modest GRR of 1.2, the
power of common alleles was 87% and rose to nearly 100% at a
Table 1. Overview of the three main GWAS scenarios.
Total
Sample Size Phase 1 Phase 2
Cases/controls HapMap panel Cases/controls HapMap panel
10,000 2,500/2,500 CEU 2,500/2,500 CEU, TSI, CHB, CHD, JPT, YRI, MKK, LWK, ASW, MXL, or GIH
20,000 5,000/5,000 CEU 5,000/5,000 CEU, TSI, CHB, CHD, JPT, YRI, MKK, LWK, ASW, MXL, or GIH
80,000 10,000/10,000 CEU 30,000/30,000 CEU, TSI, CHB, CHD, JPT, YRI, MKK, LWK, ASW, MXL, or GIH, or CEU+CHB+YRI
or CEU+CHB+YRI+MXL+GIH+ASW or CEU+CHB+YRI+MXL+GIH+ASW
doi:10.1371/journal.pone.0012600.t001
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detect an association remained low. For a GRR of 1.1 or 1.2,
power for SNPs with 1–5% frequency was essentially zero, but
rose to 65% when GRR was 1.5. Increasing the effect size reduced
the minimum allele frequency at which an association could be
detected. For a variant of 3% frequency, there was virtually no
power to detect at an effect size of 1.2 but almost 60% power to
detect it at a GRR of 1.4.
For a sample size of 80,000 samples, power to detect an
association of a lower frequency allele (MAF #5%) remained low
at smaller effect sizes. Power is ,3% at GRR=1.1 (but ,89% for
common variants with the same effect size), and did not rise above
the 80% power threshold until a GRR of 1.3 (Table S3).
Next we compared the two European samples (CEU and TSI)
in phase 2 and found that the aggregate estimates for both
populations were very similar for all scenarios considered. A power
gain in TSI could be observed for lower-frequency variants at
smaller total sample sizes (10,000 and 20,000), including variants
that appear monomorphic in CEU (which by definition cannot
contribute power). This effect, however, was balanced by a power
loss in TSI for the largest sample size (80,000), due to the total
number of monomorphic SNPs in TSI (241,688 SNPs compared
to 199,821 monomorphic SNPs in CEU; Figure S1) and the
amplification of their inability to contribute power by the large
number of samples.
Performing phase 2 of the GWAS in a non-European
population panel demonstrated a marked power gain for alleles
with low frequency in CEU (MAF #5%), in a trend that remained
true with increasing sample size or greater effect sizes (Figure 1
and Figure S2 for alleles of 5–10% frequency in CEU). Any of
the African population panels (YRI, MKK, or LWK) and the
admixed African-American (ASW) panel provided the greatest
power gain as compared to a GWAS performed in CEU samples.
For a sample size of 20,000, the power to detect low-frequency
variants (MAF #5%) with a GRR of 1.2 was close to zero in CEU,
but about 40% in YRI. At a GRR of 1.4, power was about 50% in
CEU but 80% in the African population samples. These results
demonstrate that there is a notable gain in power for this class of
variants by moving into an African population sample for phase 2.
Power for alleles of low frequency in CEU also increased by
performing phase 2 in samples from one of the East-Asian
populations (CHB, CHD, or JPT) though the gain was not as
significant as that provided by moving to an African population
sample or a sample from the admixed ASW panel in phase 2. The
other admixed population panels (GIH, MXL) also improved
power, but to a lesser degree than one of the East-Asian panels.
For a sample size of 80,000, performing phase 2 of the GWAS
in a non-European population sample continued to yield a net
gain in power, but only for those alleles that have low frequency in
CEU and for smaller effect sizes (Figure 2). For larger effect sizes
(GRR .1.3), polymorphic SNPs in CEU (especially those at lower
frequency where power can still be improved) continued to gain in
power, while the power for many of the other populations reached
a plateau due to a comparatively larger slice of apparently
monomorphic SNPs (Figure S1), an effect due to ascertainment
bias of the SNP genotyping platforms used in HapMap 3.
Figure 1. Power to detect association for lower-frequency alleles (#5%) in CEU based on HapMap 3 data. Power is given for various
individual population panels (CEU, TSI, YRI, MKK, LWK, and ASW), a panel with major continental representation (CEU+CHB+YRI) and a cosmopolitan
panel with major continental representation and admixed populations (GIH, MXL, and ASW) interrogated in phase 2, aggregated over those alleles
that have lower frequency (1–5%) in CEU.
doi:10.1371/journal.pone.0012600.g001
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in phase 2. One multiethnic sample comprised the major
continental population panels (CEU+YRI+CHB) while the second
comprised the major continental panels in addition to the admixed
panels (CEU+YRI+CHB+GIH+MXL+ASW). Although the power
gain for alleles of lower frequency in CEU was noticeable in both
multiethnic panels, the best power was obtained for the ‘‘cosmo-
politan’’ panel with representation from the major continental
groups as well as the admixed populations (Figures 1 and 2).
During the course of this study, we had access to low-coverage
pilot data from the 1000 Genomes Project, which allowed us to
replicate these relationships across 3,327,757 detected variable
sites with estimated allele frequencies in the CEU, CHB, JPT and
YRI panels across the whole genome, essentially free of
ascertainment bias. Overall, the power estimates based on these
allele frequency distributions were unchanged (Tables S4, S5
and S6), compared to the HapMap 3-based results, also for a
lowered discovery threshold of p,1610
28 to reflect increased
variation in African samples (data not shown).
Consistent with the HapMap 3-based results, power to detect
an association was driven primarily by common variation and
power to detect lower-frequency variants remained limited for
GWAS scenarios exclusively in European samples (Tables S4,
S5 and S6). For lower-frequency variants (MAF #5%), the 80%
power threshold was not reached until the sample size was
80,000 and the effect size was 1.3 (Figure 3), exactly as was
observed in the HapMap 3 dataset. Performing phase 2 in
African ancestry samples increased power to detect alleles of
lower frequency in CEU (Figure 4 and Figure S3 for alleles of
5–10% frequency in CEU). Power was also increased by
including samples of East-Asian ancestry in phase 2, but to a
lesser extent than samples of African ancestry. Following a
multiethnic approach by combining samples from the CEU,
CHB, JPT and YRI panels, we see again a power improvement
for lower frequency alleles (in CEU). At an effect size of 1.2 and
a total sample size of 80,000, utilizing the multiethnic approach
in phase 2 increased power to detect low-frequency variants in
CEU to 85%, in comparison to 60% power when only European
samples are tested in phase 2. These results indicate a potential
gain in power to detect alleles of lower frequency in European
samples by performing a second phase of GWAS in samples of
African descent (Figures 3 and 4).
To illustrate the impact of allele frequency differences between
populations, we focus on two specific scenarios: one GWAS in
which phase 1 and phase 2 are performed in 10,000 European
(CEU) samples (20,000 total samples), and a second GWAS in
which phase 1 tests 10,000 European (CEU) samples and phase 2
tests 10,000 African (YRI) samples (Figure 5). Of all .3 million
SNPs with allele frequency estimates in CEU and YRI from 1000
Genomes, we can identify four categories: (1) SNPs that reached
power $80% in both scenarios (65.6% of all .3 million SNPs), (2)
SNPs with power $80% in only the European GWAS (6.5%), (3)
SNPs with power $80% in only the GWAS with YRI samples in
phase 2 (9.3%), and (4) SNPs that do not reach 80% power in
either scenario (18.6%). Most of the power gain (3.3%) for the
CEU+YRI design (relative to CEU+CEU) is due to alleles that are
15–40% higher in frequency in YRI compared to CEU. For these
alleles that are 15–40% more common in YRI, the net gain in
Figure 2. Power as a function of allele frequency (#5%) in CEU based on HapMap 3 data. For a sample size of 80,000 and a modest effect
size (GRR of 1.1 and 1.2), power is given for CEU, CHB, YRI, and two multiethnic panels (‘‘major continental’’, CEU+CHB+YRI, and ‘‘cosmopolitan’’,
CEU+CHB+YRI+ASW+GIH+MXL) in phase 2. Including non-European samples in phase 2 improves power to detect an association for alleles that have
lower frequency in CEU.
doi:10.1371/journal.pone.0012600.g002
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three individual panels (CEU, CHB+JPT, YRI), and a multiethnic panel (CEU+CHB+JPT+YRI) in phase 2, aggregated over those alleles that have lower
frequency (1–5%) in CEU.
doi:10.1371/journal.pone.0012600.g003
Figure 4. Power as a function of allele frequency (#5%) in CEU using 1000 Genomes Project data. For a sample size of 80,000 and
modest effect size (GRR of 1.1 and 1.2), power is given for three individual panels (CEU, CHB+JPT, YRI) and a multiethnic panel in phase 2. Including
non-European samples in phase 2 improves power to detect an association for alleles that have lower frequency in CEU.
doi:10.1371/journal.pone.0012600.g004
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of high frequency in CEU is saturated with little room for
improvement; including more European samples will contribute
only limited additional power. Power for alleles of lower frequency
in CEU is certainly not saturated, and including samples of
African descent in phase 2 results in a marked power gain for those
polymorphisms that are relatively common in the African
population. The gain in power resulting from using samples of
African descent in phase 2 appears to be largely driven by alleles
that have higher frequency in African samples than in European
samples (Table 2).
Lastly, we tested how allele frequency differences between
populations could influence the power (or sample size required) for
replicating a reported association (Table S7). For 182 (unique)
SNPs previously described as bona fide associations discovered in a
European sample, we found that 57 SNPs (30% of the reported
associations) required a total sample size of at least 2,500 (with a
case/control ratio of 1:1) to replicate the observed effect at 80%
power in another European population sample. Performing
replication studies in a non-European population may change
the required sample size, reflecting allele frequency changes
between populations (assuming a constant effect size). For 90
Figure 5. The relationship between allele frequency differences between CEU and YRI and power. We plot the histogram of all SNPs in
the 1000 Genomes Project data as a function the allele frequency difference between CEU and YRI (excluding SNPs monomorphic in both CEU and
YRI). The histogram is colour-coded by the estimated change in power by performing phase 2 in YRI instead of CEU, assuming a total sample size of
20,000 (10,000 in CEU in phase 1, and 10,000 in YRI in phase 2) and a GRR of 1.2. Allele frequency differences from +15% to +40% in YRI result in a
positive gain in power (in red), which is compensated by SNPs that are common in CEU (in blue). We divide the histogram into 4 categories: (1) SNPs
with at least 80% power in both scenarios (CEU in phase 2 or YRI in phase 2) (65.6% of all SNPs considered), (2) SNPs with at least 80% power to
detect an association in the European GWAS (CEU in phase 2) (6.5% of all SNPs considered), (3) SNPs with at least 80% power in the African GWAS (YRI
in phase 2) (9.3%), and (4) SNPs that do not reach 80% in either of these two scenarios (18.6%). As alleles of higher frequency in CEU are mostly
saturated for power, including additional European samples in GWAS will only marginally increase power, whereas alleles of lower frequency in CEU
may substantially benefit in terms of power from elevated frequencies in African populations.
doi:10.1371/journal.pone.0012600.g005
Table 2. Number of SNPs with higher or lower minor allele frequency in YRI or CHB+JPT, as compared to CEU in Pilot 1 of 1000
Genomes.
Allele Frequency Difference YRI (% of total SNPs) CHB+JPT (% of total SNPs)
Less common in CEU 1499386 (45.06%) 1518752 (45.64%)
Equal to CEU 14321 (0.43%) 93843 (2.82%)
More common in CEU 1814051 (54.51%) 1715163 (51.54%)
We have ignored allele flips (where the minor allele in CEU is the major allele in YRI or CHB+JPT), in order to estimate how many SNPs would be expected to have better
power in YRI or CHB+JPT (due to a higher minor allele frequency).
doi:10.1371/journal.pone.0012600.t002
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achieved, as the effect could be replicated in a non-European
population with a smaller sample size than that required in a
European population. On the other hand, for 42 (22%) of the
reported associations, the sample size required for replication in a
non-European population was greater than that required for
replication in a European population.
Discussion
In this work, we have performed a quantitative analysis of how
allele frequency differences between populations affect the power
of genome-wide association studies, conditional on a first wave of
GWAS performed strictly in European samples. Probably the most
important observation is that genome-wide studies in a diverse set
of population samples can offer improved power for discovery as
compared to a study that exclusively focuses on European
population samples, and that this effect is dominated by those
alleles at lower frequency in European populations. Given the
investment made to date in GWAS of European samples, the
implication of this result is that a second, future wave of genomic
association studies would seem to benefit from broad inclusion of
non-European samples.
Our approach has limitations, however, and makes some
assumptions about the underlying genetic model that are worth
highlighting here. First, HapMap examines a biased set of SNPs
[16]. The HapMap 3 data set used here is limited to SNPs on the
Illumina Human-1M and Affymetrix 6.0 arrays. Both platforms
have a strong bias towards polymorphisms of high frequency in
European populations, and provide rather poor representation of
low-frequency variants or polymorphisms unique to non-Europe-
an populations. No explicit attempt was made to reconstruct (in an
unbiased way) the full allele frequency spectrum in these
populations (see, for example, [17]). Our initial aim was simply
to mimic the situation in which these arrays would be used in an
actual genome-wide study in any of the populations represented by
the HapMap 3 collection. We argue that our results for these SNPs
are relevant and realistic, since these arrays are still today state-of-
the-art in terms of their SNP density and coverage (though likely
not for long). Importantly, the results we obtain with the 1000
Genomes Project pilot data directly address this concern. Whole-
genome sequencing resulted in near-complete ascertainment of
3,327,757 variants in the same HapMap samples, essentially free
of ascertainment bias. Our calculations based on these variants in
the four HapMap panels still indicate that a multiethnic approach
for future disease studies is going to improve power to discover
novel susceptibility loci.
Second, we limited the HapMap 3 analysis to only 100 founder
chromosomes in each of the populations to ensure identical
precision in the allele frequency estimates of the respective
populations. Consequently, we are unable to simulate power for
lower-frequency or rare variants. The rapid advances in DNA
sequencing platforms will help build the tools to query those
variants in the near future in a comprehensive fashion, mitigating
some of the shortcomings of HapMap-inspired SNP arrays. In the
absence of empirical data on lower-frequency variants in this
study, however, we predict that a multiethnic approach will also be
beneficial for the study of rare variation, given that rare variation
is more likely to be population-specific.
Third, we have made no attempt to model the LD between
the (hidden) causal variant and the tested SNPs. For many
susceptibility loci, the genetic architecture of risk alleles remains
unknown despite ferocious efforts to fine-map the genetic
culprits. For the sake of simplicity, our aim was to simulate
the observed behavior of associations at common (tag) SNPs
consistent with validated associations recorded to date, regard-
less of the constellation of causal variants underlying them. In a
scenario where a tag SNP captures the causal variant in a
consistent manner across multiple populations, this approxima-
tion would not be expected to change the result. However, if the
LD structure between the tag SNP and the causal variant is
markedly different between populations, this could lead to a
reduction of power. An extreme example is what others have
referred to as the ‘‘flip-flop’’ phenomenon, where different
populations can show opposite directions of the effect at the tag
SNP (that is, risk in one population and protective in another)
[18,19]. Although it is at present unclear how widespread this
phenomenon is, we emphasize that this concern will be
alleviated when all polymorphisms can be directly tested (either
through complete sequencing or through whole-genome impu-
tation). Either way, sequencing data, such as that generated by
the 1000 Genomes Project, will help mitigate concerns about
underlying LD patterns. The results based on the 1000 Genomes
Project data (with much more complete representation of
variation across the genome) clearly indicate that, as long as
the effect is shared across populations, using samples from non-
European populations can yield a gain in power for discovery.
The general agreement with the 1000 Genomes results also
indicates that the ascertainment bias of the HapMap 3 data was
not a significant limitation, at least for the purposes of this
analysis.
Fourth, the disease model employed assumes that the effect
size is constant between populations. In other words, we have
not specifically modeled biological heterogeneity of the allelic
effect, or accounted for phenotype differences (including
incidence rate or prevalence) between populations. It remains
to be seen to what extent the effects of causal variants are
variable between populations, but so far the evidence for
common polymorphisms seems to suggest that heterogeneity is
limited with reproducible effect sizes between populations
(including the KCNQ1 example that motivated this study), even
if for most of the bona fide loci we still do not know the causal
variants driving the effect. Under a model of biological
heterogeneity for a given locus, we expect the power benefit to
evaporate only in the scenario that the causal effect is only
present in specific populations, or in the more extreme scenario
that the effect is even reversed.
Lastly, we have not dealt with the practical problem of
population stratification, where the test statistic can be inflated
due to intrinsic allele frequency differences between cases and
controls (due to some bias in ancestry in both groups). Our results
are based on ideal conditions where cases and controls are, by
definition, sampled from the same population. Yet, it is worth
pointing out the potential pitfalls of not correcting for population
structure in association analyses [20].
We have focused only on the discovery of novel loci, not on
fine-mapping causal variants within already established loci.
The localization of the causal variants is a different question
beyond the scope of this analysis, but a multiethnic approach
will likely be helpful for that purpose as well, as linkage
disequilibrium differences between populations can be exploited
to narrow the genomic window that harbors the causal variant
[21,22]. Altogether, this analysis gives a robust indication of the
potential benefit of performing whole-genome association
studies in a diverse set of population samples, a strategy that
has thus far been underutilized [4]. This benefit can be expected
for data sets acquired using SNP arrays as well as data from
sequencing.
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Text S1 R script for computing power.
Found at: doi:10.1371/journal.pone.0012600.s011 (0.03 MB
DOC)
Figure S1 Number of monomorphic SNPs in the HapMap 3
population panels. The number of monomorphic SNPs in each
population panel are displayed, stratified by minor allele frequency
in CEU.
Found at: doi:10.1371/journal.pone.0012600.s001 (1.94 MB TIF)
Figure S2 Power to detect an association for common alleles (5–
10%) based on HapMap 3 data. The impact on power of
switching to non-European samples in stage 2 of the GWAS is
limited primarily to alleles of lower frequency in CEU. Testing
non-European samples for alleles of common frequency in CEU
yields a small (or no) increase in power.
Found at: doi:10.1371/journal.pone.0012600.s002 (1.93 MB TIF)
Figure S3 Power to detect an association for common alleles (5–
10%) based on 1000 Genomes data. Consistent with our
observations in the HapMap data, the improvement in power
achieved by using non-European samples is limited to alleles of
lower frequency in CEU.
Found at: doi:10.1371/journal.pone.0012600.s003 (1.93 MB TIF)
Table S1 Power to detect an association for a sample size of
10,000 using HapMap 3 data. Power is aggregated over all 1.4
million SNPs, over lower-frequency (1–5%) alleles, and over
subsets of SNPs stratified by minor allele frequency in CEU.
Calculations were made using allele frequencies from all 11
HapMap 3 population panels. GRR is varied between 1.1 and 1.5.
Data points referred to in the paper and in figures appear in bold.
Found at: doi:10.1371/journal.pone.0012600.s004 (0.03 MB
XLS)
Table S2 Power to detect an association for a sample size of
20,000 using HapMap 3 data. Calculations were made using
HapMap 3 data. Data points referred to in the paper and in
figures appear in bold.
Found at: doi:10.1371/journal.pone.0012600.s005 (0.03 MB
XLS)
Table S3 Power to detect an association for a sample size of 80,000
using HapMap 3 data. Power is calculated for individual population
panels as well as multiethnic GWAS, in which samples for stage 2 of
the GWAS are drawn from the major continental population panels
or the major continental plus the admixture population panels. Data
points referred to in the paper and in figures appear in bold.
Found at: doi:10.1371/journal.pone.0012600.s006 (0.04 MB
XLS)
Table S4 Power to detect an association for a sample size of
10,000 using 1000 Genomes data. Population panels in the 1000
Genomes data are CEU, CHB+JPT, and YRI. Data points
referred to in the paper and in figures appear in bold.
Found at: doi:10.1371/journal.pone.0012600.s007 (0.02 MB
XLS)
Table S5 Power to detect an association for a sample size of
20,000 using 1000 Genomes data. Data points referred to in the
paper and in figures appear in bold.
Found at: doi:10.1371/journal.pone.0012600.s008 (0.02 MB
XLS)
Table S6 Power to detect an association for a sample size of
80,000 using 1000 Genomes data. Power for individual population
panels as well as multiethnic GWAS is calculated for this sample
size, as in the HapMap 3 analysis. Data points referred to in the
paper and in figures appear in bold.
Found at: doi:10.1371/journal.pone.0012600.s009 (0.03 MB
XLS)
Table S7 Sample size needed to replicate known GWAS
findings in samples from HapMap 3 population panels. The
sample size needed to replicate a GWAS finding at $80% power
is reported for each of the 11 HapMap 3 population panels.
Sample sizes listed as ‘‘NA’’ are annotated as such because the
particular SNP is monomorphic in that population panel. SNPs
that do not reach 80% power for 150,000 samples are footnoted
and power at 150,000 samples is given.
Found at: doi:10.1371/journal.pone.0012600.s010 (0.06 MB
XLS)
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